Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis

Lung Cancer

Volumn 85, Issue 2, 2014, Pages 230-238

  Popat, Sanjay ^a   Mok, Tony ^b   Yang, James Chih Hsin ^c   Wu, Yi Long ^d   Lungershausen, Juliane ^e   Stammberger, Uz ^e   Griebsch, Ingolf ^e   Fonseca, Tiago ^f   Paz Ares, Luis ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f IQVIA   (United States)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Afatinib; Chemotherapy; Epidermal growth factor receptor (EGFR); Erlotinib; Gefitinib; NSCLC; Tyrosine kinase inhibitor

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; LUNG NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PROPORTIONAL HAZARDS MODEL;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 84904121368     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.05.007     Document Type: Article

References (50)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Socinski M.A., Crowell R., Hensing T.E., Langer C.J., Lilenbaum R., Sandler A.B., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:277S-289S.
3. Shepherd F.A., Bunn P.A., Paz-Ares L. Lung cancer in 2013: state of the art therapy for metastatic disease. Am Soc Clin Oncol Educ Book 2013, 33:339-346.
4. Buettner R., Wolf J., Thomas R.K. Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol 2013, 31:1858-1865.
5. Cufer T., Ovcaricek T., O'Brien M.E. Systemic therapy of advanced non-small cell lung cancer: major developments of the last 5 years. Eur J Cancer 2013, 49:1216-1225.
6. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11:121-128.
7. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
8. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
9. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12:735-742.
10. Li D., Ambrogio L., Shimamura T., Kubo S., Takahashi M., Chirieac L.R., et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
11. Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012, 343:342-350.
12. Sequist L.V., Yang J.C., Yamamoto N., O'Byrne K., Hirsh V., Mok T., et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013, 31:3327-3334.
13. Wu YL, Zhou C, Feng J, Lu S, Huang Y, Li W, et al. LUX-Lung 6: phase III study of afatinib versus gemcitabine/cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harbouring EGFR activating mutations. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-1 June 2013.
14. Paz-Ares L., Soulieres D., Melezinek I., Moecks J., Keil L., Mok T., et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis. J Cell Mol Med 2010, 14:51-69.
15. Hoaglin D.C., Hawkins N., Jansen J.P., Scott D.A., Itzler R., Cappelleri J.C., et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011, 14:429-437.
16. Jansen J.P., Fleurence R., Devine B., Itzler R., Barrett A., Hawkins N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011, 14:417-428.
17. Boch C., Kollmeier J., Roth A., Stephan-Falkenau S., Misch D., Gruning W., et al. The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. BMJ Open 2013, 3. pii:e002560.
18. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Eastern Cooperative Oncology Group, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
19. Centre for Reviews and Dissemination Systematic reviews: CRD's guidance for undertaking reviews in health care 2009, Centre for Reviews and Dissemination, York, UK.
20. National Institute for Health and Clinical Excellence Single technology appraisal (STA) - specification for manufacturer/sponsor submission of evidence, London 2009, http://www.nice.org.uk/aboutnice/howwework/devnicetech/SpecificationForManufacturerSponsorSubmissionOfEvidence.jsp%3Fdomedia=1%26mid=97E2DC44-19B9-E0B5-D4F73F1DB153AA86.
21. Stone A.M., Bushnell W., Denne J., Sargent D.J., Amit O., Chen C., et al. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group. Eur J Cancer 2011, 47:1763-1771.
22. Pignatti F., Hemmings R., Jonsson B. Is it time to abandon complete blinded independent central radiological evaluation of progression in registration trials?. Eur J Cancer 2011, 47:1759-1762.
23. Amit O., Mannino F., Stone A.M., Bushnell W., Denne J., Helterbrand J., et al. Blinded independent central review of progression in cancer clinical trials: results from a meta-analysis. Eur J Cancer 2011, 47:1772-1778.
24. Lunn D., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
25. Welton N.J., Caldwell D.M., Adamopoulos E., Vedhara K. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. Am J Epidemiol 2009, 169:1158-1165.
26. Burnham K.P., Anderson D.R. Model selection and multi-model inference: a practical information-theoretic approach 2002, Springer, New York; London. 2nd ed.
27. Welton N.J., Sutton A.J., Cooper N.J., Abrams K.R., Ades A.E. Evidence synthesis for decision making in healthcare 2012, John Wiley & Sons, Ltd, Chichester, UK.
28. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362:2380-2388.
29. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Seto T., et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). ASCO Meet Abs 2012, 30:7521.
30. Inoue A., Kobayashi K., Maemondo M., Sugawara S., Oizumi S., Isobe H., et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR mutations. ASCO Meet Abs 2011, 29:7519.
31. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
32. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De Rosa F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25:1545-1552.
33. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012, 30:1122-1128.
34. Chang W.C., Liaw C-C., Chen C-H. Randomized phase II study of vinorelbine plus cisplatinum versus gemcitabine plus cisplatinum in advanced non-small cell lung cancer: a preliminary result. Proc Am Soc Clin Oncol 2001, 20. Abstract 1339.
35. Comella P., Frasci G., Panza N., Manzione L., De Cataldis G., Cioffi R., et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000, 18:1451-1457.
36. Fossella F., Pereira J.R., von Pawel J., Pluzanska A., Gorbounova V., Kaukel E., et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
37. Gridelli C., Gallo C., Shepherd F.A., Illiano A., Piantedosi F., Robbiati S.F., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3025-3034.
38. Mazzanti P., Massacesi C., Rocchi M.B., Mattioli R., Lippe P., Trivisonne R., et al. Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2003, 41:81-89.
39. Melo M.J., Barradas P., Costa A. Results of a randomized phase III trial comparing 4 cisplatin (P)-based regimens in the treatment of locally advanced and metastatic non-small cell lung cancer (NSCLC): mitomycin/vinblastine/cisplatin (MVP) is no longer a therapeutic option. Proc Am Soc Clin Oncol 2002, 21. Abstract 1205.
40. Rosell R., Gatzemeier U., Betticher D.C., Keppler U., Macha H.N., Pirker R., et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002, 13:1539-1549.
41. Scagliotti G.V., De Marinis F., Rinaldi M., Crino L., Gridelli C., Ricci S., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
42. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
43. Smit E.F., van Meerbeeck J.P., Lianes P., Debruyne C., Legrand C., Schramel F., et al. Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group - EORTC 08975. J Clin Oncol 2003, 21:3909-3917.
44. Thomas P., Robinet G., Gouva S., Fournel P., Lena H., Le Caer H., et al. Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe francais de pneumo-cancerologie). Lung Cancer 2006, 51:105-114.
45. Zatloukal P., Petruzelka L., Zemanova M., Kolek V., Skrickova J., Pesek M., et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial. Lung Cancer 2003, 41:321-331.
46. ® (afatinib) 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/201292s000lbl.pdf.
47. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005, 47:69-80.
48. Ardizzoni A., Boni L., Tiseo M., Fossella F.V., Schiller J.H., Paesmans M., et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007, 99:847-857.
49. Scagliotti G., Hanna N., Fossella F., Sugarman K., Blatter J., Peterson P., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
50. Liang W., Wu X., Fang W., Zhao Y., Yang Y., Hu Z., et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 2014, 9:e85245.